NCI-2022-03173

A Phase III, Double-blind, Randomised, Placebo-Controlled,International Study to assess the Efficacy and Safety of Adjuvant Osimertinib versus Placebo in Participants with EGFR mutation-positive Stage IA2-IA3 Non-small Cell Lung Cancer, following Complete Tumour Resection (ADAURA2)

The ADAURA2 study, a Phase III trial, seeks to assess the efficacy and safety of osimertinib compared to a placebo in patients with early-stage lung cancer harboring the EGFR mutation, following complete tumor resection. This international, double-blind, randomized study aims to determine if osimertinib after surgery can prevent cancer recurrence after surgery in this specific patient population.

EGFR mutation: Epidermal Growth Factor Receptor (EGFR) is on the surface of cells and helps them grow and divide. In cancer, EGFR is like a switch that gets stuck in the "on" position, making cells grow and divide too much.

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT05120349

Clinical Trial Site: Columbia

To see all available clinical trials click here.